menu
    • menu
    [{"orgOrder":0,"company":"AnGes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AnGes \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ Not Applicable"},{"orgOrder":0,"company":"AnGes","sponsor":"Emendo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"OMNI nuclease","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"AnGes","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"AnGes \/ AnGes","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ AnGes"},{"orgOrder":0,"company":"AnGes","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AG0302-COVID19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AnGes \/ Brickell Biotech","highestDevelopmentStatusID":"7","companyTruncated":"AnGes \/ Brickell Biotech"},{"orgOrder":0,"company":"AnGes","sponsor":"Er-Kim","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Beperminogene Perplasmid","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AnGes \/ Er-Kim","highestDevelopmentStatusID":"12","companyTruncated":"AnGes \/ Er-Kim"},{"orgOrder":0,"company":"AnGes","sponsor":"Emendo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"EMD-101","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AnGes","amount2":0.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"","sponsorNew":"AnGes \/ AnGes","highestDevelopmentStatusID":"4","companyTruncated":"AnGes \/ AnGes"},{"orgOrder":0,"company":"AnGes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"AG0302-COVID19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AnGes \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Not Applicable"},{"orgOrder":0,"company":"AnGes","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Lonafarnib","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AnGes \/ AnGes","highestDevelopmentStatusID":"12","companyTruncated":"AnGes \/ AnGes"},{"orgOrder":0,"company":"AnGes","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnGes \/ AnGes","highestDevelopmentStatusID":"12","companyTruncated":"AnGes \/ AnGes"}]

    Find Clinical Drug Pipeline Developments & Deals by AnGes

    Menu

    AnGes

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonafarnib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eiger and AnGes Receive Approval for Zokinvy® for Hutchinson-Gilford Progeria in Japan

                            Details : Zokinvy (lonafarnib) is a first-in-class farnesyltransferase inhibitor. It is approved for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.

                            Brand Name : Zokinvy

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 18, 2024

                            Lead Product(s) : Lonafarnib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonafarnib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercializatio...

                            Details : Under the terms of the agreement, AnGes is responsible for obtaining and maintaining regulatory approval for Zokinvy (lonafarnib) in Japan and will be the exclusive partner for distribution and commercialization.

                            Brand Name : Zokinvy

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 10, 2022

                            Lead Product(s) : Lonafarnib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EMD-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Emendo Biotherapeutics

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            EmendoBio Gene Editing Company Acquired by AnGes, Inc.

                            Details : EmendoBio to operate as an independent subsidiary of AnGes with full access to AnGes’ global development resources to accelerate development and manufacturing capabilities for EmendoBio’s dual OMNI™ genome editing technology platforms.

                            Brand Name : EMD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 15, 2020

                            Lead Product(s) : EMD-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Emendo Biotherapeutics

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG0302-COVID19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Japan's AnGes Begins Phase 2/3 Clinical Trial Of DNA-Based COVID-19 Vaccine

                            Details : The trials involve 500 people. A group of 250 people will be vaccinated twice with AG0302-COVID19, in an interval of two weeks; the second group of 250 people twice with an interval of four weeks.

                            Brand Name : AG0302-COVID19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 08, 2020

                            Lead Product(s) : AG0302-COVID19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beperminogene Perplasmid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Er-Kim

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AnGes and Er-Kim Enter Into an Agreement for the Commercialization of Collategene® in Turkey

                            Details : Under the terms of the agreement, Er-Kim will have the exclusive rights to commercialize Collategene® in Turkey after obtaining the necessary regulatory approvals.

                            Brand Name : Collategene

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 08, 2020

                            Lead Product(s) : Beperminogene Perplasmid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Er-Kim

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG0302-COVID19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Fresh Tracks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AnGes Anoounces Collaboration Agreement with Brickell Biotech

                            Details : AnGes is currently conducting Phase 1/2 clinical studies with its vaccine candidate in Japan, and the results from these studies will guide AnGes’ and Brickell’s global development efforts of this novel vaccine candidate.

                            Brand Name : AG0302-COVID19

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 08, 2020

                            Lead Product(s) : AG0302-COVID19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Fresh Tracks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNA vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anges to develop coronavirus vaccine with Osaka University

                            Details : The company is working on the developement of a prophylactic DNA vaccine for COVID-19 using plasmid DNA production technology.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 05, 2020

                            Lead Product(s) : DNA vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnGes

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMNI nuclease

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Recipient : Emendo Biotherapeutics

                            Deal Size : $61.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics

                            Details : The funding will accelerate novel OMNI gene editing platform into a broad therapeutic product pipeline.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 15, 2020

                            Lead Product(s) : OMNI nuclease

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Recipient : Emendo Biotherapeutics

                            Deal Size : $61.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth